Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...

(RTTNews) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP in single-dose vials ...

Please provide your email address to receive an email when new articles are posted on . Intraosseous vancomycin levels were minimally detected at the end of the procedure vs. IV vancomycin levels.

COPENHAGEN, Denmark & BUFFALO GROVE, IL.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

LONDON, May 1, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical ...

Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas Products feature ready-to-use formulations to ...

LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix ...

Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...